Bruce Haffty, MD, and Mutlay Sayan, MD, on building radiation oncology at Rutgers, the future of the field, and a remarkable journey from eastern Turkey to Harvard faculty.
|Articles|January 1, 1997
Oncology NEWS International
- Oncology NEWS International Vol 6 No 1
- Volume 6
- Issue 1
Cancer Care's AIDS Pain Booklet Available
NEW YORK--Cancer Care, Inc. has a new booklet, "Pain in HIV/AIDS: Control Your Pain So It Doesn't Control You," that provides information about pain management to people with HIV, to help them advocate for themselves and receive
Advertisement
NEW YORK--Cancer Care, Inc. has a new booklet, "Pain in HIV/AIDS:Control Your Pain So It Doesn't Control You," that provides informationabout pain management to people with HIV, to help them advocate for themselvesand receive effective pain management. For free copies, call Cancer Careat 212-221-3300 or toll-free at 1-800-813-4673.
Articles in this issue
almost 30 years ago
New Board to Deal With Cancer Policy Issuesalmost 30 years ago
MoAb Shows Positive Results in Lymphoma Patientsalmost 30 years ago
Prostate Cancer Gene Location Narrowed to Chromosome 1 Armalmost 30 years ago
New BCG Bladder Cancer Indication Gets Panel Nodalmost 30 years ago
Panel Advises FDA To OK Letrozole for Advanced Breast Canceralmost 30 years ago
Limited Diagnostic Testing After Breast Cancer Treatment Urgedalmost 30 years ago
Pressures of Managed Care Spur Interest in Clinical Guidelinesalmost 30 years ago
Baltimore Will Head New Effort To Develop a Vaccine for HIValmost 30 years ago
Epidemiologist Challenges Tamoxifen, Second Cancer Linkalmost 30 years ago
AIDS Center Director Offers Advice on Selecting a PhysicianAdvertisement
Related to this article
Marcio A. Fagundes, MD, discussed disease control by risk group among 404 patients with prostate cancer treated with intensity-modulated proton therapy.
The approval expands the indication of pirtobrutinib to patients with previously untreated chronic lymphocytic leukemia/small lymphocytic lymphoma with no known 17p deletion.
Community physicians must be “smart” when it comes to initiating outpatient care with agents like ramantamig for multiple myeloma, according to Jeffrey V. Matous, MD.
In the phase 3 Alliance A071801 trial, postoperative fractionated SRS improved surgical bed control vs single-fraction SRS without added toxicity.
In the phase 3 evERA trial, interim overall survival data showed a positive trend in favor of giredestrant/everolimus vs endocrine therapy plus everolimus.
William A. Hall, MD, reviews resection rates, surgical complications, and SBRT target volumes from the SOFT Preop study in pancreatic cancer.
Andy Liao, MD, discusses the distribution of KRAS mutations in biliary tract cancer and the different classes of KRAS inhibitors in development.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA OKs Pirtobrutinib in Frontline CLL/SLL
2
Assessing IMPT Outcomes Across Localized Prostate Cancer Risk Groups
3
EXCALIBER-RRMM: Iberdomide in Relapsed/Refractory Multiple Myeloma
4
SBRT Matches Disease Control of Prostatectomy in Localized Prostate Cancer
5